Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation.

Rissling O, Naik M, Brakemeier S, Schmidt D, Staeck O, Hohberger A, Neumayer HH, Budde K.

Clin Kidney J. 2018 Aug;11(4):564-573. doi: 10.1093/ckj/sfx145. Epub 2018 Jan 12.

2.

The selective biomarker IL-8 identifies IFTA after kidney transplantation in blood cells.

Matz M, Lorkowski C, Fabritius K, Wu K, Rudolph B, Frischbutter S, Brakemeier S, Gaedeke J, Neumayer HH, Mashreghi MF, Budde K.

Transpl Immunol. 2016 Nov;39:18-24. doi: 10.1016/j.trim.2016.09.003. Epub 2016 Sep 29.

PMID:
27693310
3.

Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation.

Matz M, Lorkowski C, Fabritius K, Durek P, Wu K, Rudolph B, Neumayer HH, Mashreghi MF, Budde K.

Transpl Immunol. 2016 Nov;39:52-59. doi: 10.1016/j.trim.2016.09.001. Epub 2016 Sep 20.

PMID:
27663089
4.

IL-17 Expression in the Time Course of Acute Anti-Thy1 Glomerulonephritis.

Loof T, Krämer S, Gaedeke J, Neumayer HH, Peters H.

PLoS One. 2016 May 31;11(5):e0156480. doi: 10.1371/journal.pone.0156480. eCollection 2016.

5.

Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.

Matz M, Fabritius K, Liu J, Lorkowski C, Brakemeier S, Unterwalder N, Dürr M, Mashreghi MF, Neumayer HH, Budde K.

Transpl Immunol. 2015 Nov;33(3):176-84. doi: 10.1016/j.trim.2015.10.002. Epub 2015 Oct 20.

PMID:
26478531
6.

The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.

Wu K, Budde K, Schmidt D, Neumayer HH, Lehner L, Bamoulid J, Rudolph B.

Clin Transplant. 2016 Feb;30(2):105-17. doi: 10.1111/ctr.12645. Epub 2016 Jan 5.

PMID:
26448478
7.

Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood.

Matz M, Fabritius K, Lorkowski C, Dürr M, Gaedeke J, Durek P, Grün JR, Goestemeyer A, Bachmann F, Wu K, Rudolph B, Schmidt D, Weber U, Haftmann C, Unterwalder N, Lachmann N, Radbruch A, Neumayer HH, Mashreghi MF, Budde K.

Transplantation. 2016 Apr;100(4):898-907. doi: 10.1097/TP.0000000000000873.

PMID:
26444957
8.

Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, Andersson K, Wehner M, Kozik-Jaromin J, Brett S, Hasslacher J, Stover JF, Peters H, Neumayer HH, Kindgen-Milles D.

Crit Care. 2015 Sep 29;19:349. doi: 10.1186/s13054-015-1066-7.

9.

Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.

Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhynov D.

Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.

10.

Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia.

Stancu B, Krämer S, Loof T, Mika A, Amann K, Neumayer HH, Peters H.

J Hypertens. 2015 Sep;33(9):1907-20; discussion 1921. doi: 10.1097/HJH.0000000000000648.

PMID:
26176653
11.

No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.

Rissling O, Glander P, Hambach P, Mai M, Brakemeier S, Klonower D, Halleck F, Singer E, Schrezenmeier EV, Dürr M, Neumayer HH, Budde K.

Br J Clin Pharmacol. 2015 Nov;80(5):1086-96. doi: 10.1111/bcp.12664. Epub 2015 Jul 14.

12.

Midterm echocardiographic follow-up of cardiac function after living kidney donation.

Hewing B, Dreger H, Knebel F, Spethmann S, Poller WC, Dehn AM, Neumayer HH, Waiser J, Budde K, Halleck F.

Clin Nephrol. 2015 May;83(5):253-61.

PMID:
25899575
13.

The Relationship of the Severity and Category of Acute Rejection With Intimal Arteritis Defined in Banff Classification to Clinical Outcomes.

Wu K, Budde K, Schmidt D, Neumayer HH, Rudolph B.

Transplantation. 2015 Aug;99(8):e105-14. doi: 10.1097/TP.0000000000000640.

PMID:
25719260
14.

Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients.

Huber L, Lachmann N, Niemann M, Naik M, Liefeldt L, Glander P, Schmidt D, Halleck F, Waiser J, Brakemeier S, Neumayer HH, Schönemann C, Budde K.

Transpl Int. 2015 Jun;28(6):710-9. doi: 10.1111/tri.12533.

15.

Renal allograft loss caused by cardiorenal syndrome: frequency and diagnosis.

Waiser J, Knebel F, Rudolph B, Wu K, Müller E, Sanad W, Budde K, Neumayer HH, Halleck F.

Transplantation. 2015 Jun;99(6):1208-15. doi: 10.1097/TP.0000000000000501.

PMID:
25539469
16.
17.

Pathologic characteristics of early or late acute cellular rejection and outcome after kidney transplant.

Wu K, Budde K, Schmidt D, Neumayer HH, Rudolph B.

Exp Clin Transplant. 2014 Aug;12(4):314-22.

18.

Human leukocyte antigen-incompatible kidney transplantation after "desensitization"--hope and reality.

Neumayer HH, Budde K, Liefeldt L.

Transplantation. 2014 Oct 27;98(8):819-20. doi: 10.1097/TP.0000000000000296. No abstract available.

PMID:
25073038
19.

The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes.

Wu K, Budde K, Lu H, Schmidt D, Liefeldt L, Glander P, Neumayer HH, Rudolph B.

Transplantation. 2014 Jun 15;97(11):1146-54. doi: 10.1097/01.TP.0000441094.32217.05.

PMID:
24892962
21.

Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations.

Wu KY, Budde K, Schmidt D, Neumayer HH, Rudolph B.

Clin Transplant. 2014 Apr;28(4):410-8. doi: 10.1111/ctr.12333. Epub 2014 Mar 11.

PMID:
24617534
22.

Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation.

Khadzhynov D, Schelter C, Lieker I, Mika A, Staeck O, Neumayer HH, Peters H, Slowinski T.

J Crit Care. 2014 Apr;29(2):265-71. doi: 10.1016/j.jcrc.2013.10.015. Epub 2013 Nov 11.

PMID:
24360392
23.

The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.

Mühlbacher F, Neumayer HH, del Castillo D, Stefoni S, Zygmunt AJ, Budde K; European Rapamune Cyclosporine Minimization Study Group.

Transpl Int. 2014 Feb;27(2):176-86. doi: 10.1111/tri.12228. Epub 2013 Nov 25.

24.

Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat.

Wang-Rosenke Y, Khadzhynov D, Loof T, Mika A, Kawachi H, Neumayer HH, Peters H.

BMC Nephrol. 2013 Oct 14;14:223. doi: 10.1186/1471-2369-14-223.

25.

Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors.

Halleck F, Diederichs G, Koehlitz T, Slowinski T, Engelken F, Liefeldt L, Friedersdorff F, Fuller TF, Magheli A, Neumayer HH, Budde K, Waiser J.

Transpl Int. 2013 Dec;26(12):1208-16. doi: 10.1111/tri.12195. Epub 2013 Oct 19.

26.

Tubular von Hippel-Lindau knockout protects against rhabdomyolysis-induced AKI.

Fähling M, Mathia S, Paliege A, Koesters R, Mrowka R, Peters H, Persson PB, Neumayer HH, Bachmann S, Rosenberger C.

J Am Soc Nephrol. 2013 Nov;24(11):1806-19. doi: 10.1681/ASN.2013030281. Epub 2013 Aug 22.

27.

Treatment with sirolimus is associated with less weight gain after kidney transplantation.

Diekmann F, Campistol JM, Rovira J, Budde K, Neumayer HH, Oppenheimer F, Flechner SM.

Transplantation. 2013 Sep 15;96(5):480-6. doi: 10.1097/TP.0b013e31829a9231.

PMID:
23912169
28.

Combined standard and novel immunosuppressive substances affect B-lymphocyte function.

Matz M, Lehnert M, Lorkowski C, Fabritius K, Weber UA, Mashreghi MF, Neumayer HH, Budde K.

Int Immunopharmacol. 2013 Apr;15(4):718-25. doi: 10.1016/j.intimp.2013.02.025. Epub 2013 Mar 15.

PMID:
23499640
29.

Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.

Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Härtter S, Friedman J, Peters H, Clemens A.

Thromb Haemost. 2013 Apr;109(4):596-605. doi: 10.1160/TH12-08-0573. Epub 2013 Feb 7.

PMID:
23389759
30.

Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.

Mathia S, Paliege A, Koesters R, Peters H, Neumayer HH, Bachmann S, Rosenberger C.

Acta Physiol (Oxf). 2013 Mar;207(3):565-76. doi: 10.1111/apha.12058.

PMID:
23384425
31.

Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.

Khadzhynov D, Slowinski T, Lieker I, Neumayer HH, Albrecht D, Streefkerk HJ, Rebello S, Peters H.

Clin Pharmacokinet. 2012 Oct 1;51(10):661-9.

PMID:
23018529
32.

An evaluation of sirolimus in renal transplantation.

Halleck F, Duerr M, Waiser J, Huber L, Matz M, Brakemeier S, Liefeldt L, Neumayer HH, Budde K.

Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1337-56. doi: 10.1517/17425255.2012.719874. Epub 2012 Aug 28. Review.

PMID:
22928953
33.

Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.

Matz M, Lehnert M, Lorkowski C, Fabritius K, Unterwalder N, Doueiri S, Weber UA, Mashreghi MF, Neumayer HH, Budde K.

Transpl Int. 2012 Oct;25(10):1106-16. doi: 10.1111/j.1432-2277.2012.01537.x. Epub 2012 Jul 21.

34.

Identification and therapeutic management of highly sensitized patients undergoing renal transplantation.

Huber L, Lachmann N, Dürr M, Matz M, Liefeldt L, Neumayer HH, Schönemann C, Budde K.

Drugs. 2012 Jul 9;72(10):1335-54. doi: 10.2165/11631110-000000000-00000. Review.

PMID:
22747448
35.

Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction.

Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer HH, Peters H.

J Urol. 2012 Jul;188(1):316-23. doi: 10.1016/j.juro.2012.02.2552. Epub 2012 May 16.

PMID:
22608751
36.

Weight gain in long-term survivors of kidney or liver transplantation--another paradigm of sarcopenic obesity?

Schütz T, Hudjetz H, Roske AE, Katzorke C, Kreymann G, Budde K, Fritsche L, Neumayer HH, Lochs H, Plauth M.

Nutrition. 2012 Apr;28(4):378-83. doi: 10.1016/j.nut.2011.07.019. Epub 2012 Feb 2.

PMID:
22304858
37.

Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.

Liefeldt L, Brakemeier S, Glander P, Waiser J, Lachmann N, Schönemann C, Zukunft B, Illigens P, Schmidt D, Wu K, Rudolph B, Neumayer HH, Budde K.

Am J Transplant. 2012 May;12(5):1192-8. doi: 10.1111/j.1600-6143.2011.03961.x. Epub 2012 Feb 2.

38.

Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.

Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU.

Transplantation. 2012 Mar 15;93(5):543-50. doi: 10.1097/TP.0b013e318242162d.

PMID:
22234349
39.

Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD.

Khadzhynov D, Slowinski T, Lieker I, Spies C, Puhlmann B, König T, Uhrig A, Eggers K, Neumayer HH, Traunmüller F, Joukhadar C, Peters H.

Int J Clin Pharmacol Ther. 2011 Nov;49(11):656-65.

PMID:
22011690
40.

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.

Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2696-704. doi: 10.2215/CJN.00270111. Epub 2011 Sep 15.

41.

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

Waiser J, Budde K, Schütz M, Liefeldt L, Rudolph B, Schönemann C, Neumayer HH, Lachmann N.

Nephrol Dial Transplant. 2012 Mar;27(3):1246-51. doi: 10.1093/ndt/gfr465. Epub 2011 Aug 17.

PMID:
21852274
42.

Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction.

Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neumayer HH, Peters H.

J Urol. 2011 Sep;186(3):1142-9. doi: 10.1016/j.juro.2011.04.108. Epub 2011 Jul 23.

PMID:
21784461
43.

Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure.

Kron J, Kron S, Wenkel R, Schuhmacher HU, Thieme U, Leimbach T, Kern H, Neumayer HH, Slowinski T.

Nephrol Dial Transplant. 2012 Jan;27(1):146-52. doi: 10.1093/ndt/gfr269. Epub 2011 May 28.

PMID:
21622989
44.

Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(®)) in renal transplant recipients.

Brakemeier S, Schweiger B, Lachmann N, Glander P, Schönemann C, Diekmann F, Neumayer HH, Budde K.

Nephrol Dial Transplant. 2012 Jan;27(1):423-8. doi: 10.1093/ndt/gfr278. Epub 2011 May 25.

PMID:
21613386
45.

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).

Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F.

Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb.

PMID:
21372756
46.

Why rejections are not biopsy proven: frequency and reasons.

Fleiner F, Glander P, Fritsche L, Neumayer HH, Budde K.

Transplant Proc. 2010 Dec;42(10):4509-12. doi: 10.1016/j.transproceed.2010.09.158.

PMID:
21168726
47.

Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.

Matz M, Naik M, Mashreghi MF, Glander P, Neumayer HH, Budde K.

Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):103-13. doi: 10.1517/17425255.2011.540238. Epub 2010 Dec 8. Review.

PMID:
21142580
48.

Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.

Wehland M, Bauer S, Brakemeier S, Burgwinkel P, Glander P, Kreutz R, Lorkowski C, Slowinski T, Neumayer HH, Budde K.

Pharmacogenet Genomics. 2011 Apr;21(4):179-84. doi: 10.1097/FPC.0b013e32833ea085.

PMID:
20818295
49.

Enteric-coated mycophenolate sodium.

Budde K, Dürr M, Liefeldt L, Neumayer HH, Glander P.

Expert Opin Drug Saf. 2010 Nov;9(6):981-94. doi: 10.1517/14740338.2010.513379. Review.

PMID:
20795786
50.

Pretransplant cardiovascular evaluation and posttransplant cardiovascular risk.

Young JB, Neumayer HH, Gordon RD.

Kidney Int Suppl. 2010 Sep;(118):S1-7. doi: 10.1038/ki.2010.209. Review.

Supplemental Content

Loading ...
Support Center